Herantis Pharma Oyj
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HRPMF research report →
About the company
Herantis Pharma Oyj, a biotechnology enterprise, specializes in creating disease-modifying therapies for Parkinson's disease (PD) that harness Cerebral Dopamine Neurotrophic Factor (CDNF). Central to its developmental efforts is HER-096, a sophisticated, compact, synthetic chemical peptidomimetic originating from the active parent molecule. This preclinical xCDNF candidate is currently being investigated for its therapeutic promise in PD and other neurodegenerative conditions.
- CEO
- Antti Vuolanto D.Sc. (Tech)
- IPO
- 2018
- Employees
- 10
- HQ
- Espoo, FI
Price Chart
- Market Cap
- $59.47M
- P/E
- -7.05
- P/S
- 0.00
- P/B
- -27.19
- EV/EBITDA
- -8.31
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21354.84%
- ROIC
- -363.20%
- Revenue
- $0 · 0.00%
- Net Income
- $-4,939,000 · -1864.94%
- EPS
- $-0.24 · -1572.39%
- Op Income
- $-5,026,000
- FCF YoY
- -41.18%
- 52W High
- $3.51
- 52W Low
- $3.51
- 50D MA
- $3.51
- 200D MA
- $3.51
- Beta
- 0.43
- Avg Volume
- 0
Get TickerSpark's AI analysis on HRPMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HRPMF coverage
Recent articles, reports, and earnings notes.
No research on HRPMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HRPMF report →Similar companies
Peers in the same neighborhood.